| abstract |
Controlled release and delayed release formulations which are adapted or intended fornoral administration and which contain paroxetine hydrochloride, such as anformulation which is a system for the controlled and delayed release of paroxetinenhydrochloride, having (a) a deposit-core comprising 28.61 mg paroxetinenhydrochloride, 18.7 mg methocel K4M, 79.14 mg lactose monohydrate, 2.50 mgnpolyvinylpyrrolidone, 1.25 mg magnesium stearate, and 0.50 mg Syloid 244, and (b)na support-platform applied to said deposit-core comprising 15.04 mg Compritol 888,n30.50 mg lactose monohydrate, 4.00 mg polyvinylpyrrolidone, 0.80 mg magnesiumnstearate, 29.32 mg methocel E5, 0.32 mg Syloid 244, and 0.02 mg iron oxide; and (c)nan enteric coating comprising 13.27 mg Eudragit, 3.31 mg talc, and 1.33 mg triethylncitrate, may be used to treat a variety of disorders including depression. |